VEA
XENE icon

Virtus ETF Advisers’s Xenon Pharmaceuticals XENE Stock Holding History

Virtus ETF Advisers’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,802
Closed -$70.6K – 804
2024
Q4 		$70.6K Sell
1,802
-623
-26% -$25.8K 0.03% 372
2024
Q3 		$95.5K Buy
2,425
+45
+2% +$1.81K 0.04% 383
2024
Q2 		$92.8K Buy
2,380
+277
+13% +$11.1K 0.05% 346
2024
Q1 		$90.5K Sell
2,103
-142
-6% -$6.53K 0.05% 381
2023
Q4 		$103K Sell
2,245
-79
-3% -$2.79K 0.07% 346
2023
Q3 		$79.4K Sell
2,324
-228
-9% -$8.53K 0.05% 362
2023
Q2 		$98.3K Sell
2,552
-58
-2% -$2.31K 0.06% 392
2023
Q1 		$93.4K Sell
2,610
-1,006
-28% -$37.2K 0.05% 352
2022
Q4 		$143K Sell
3,616
-57
-2% -$2.08K 0.07% 358
2022
Q3 		$133K Buy
3,673
+30
+0.8% +$1.08K 0.05% 373
2022
Q2 		$111K Sell
3,643
-2,435
-40% -$73.6K 0.04% 406
2022
Q1 		$186K Sell
6,078
-361
-6% -$10.8K 0.08% 202
2021
Q4 		$201K Sell
6,439
-5,055
-44% -$151K 0.08% 208
2021
Q3 		$176K Sell
11,494
-597
-5% -$10.4K 0.08% 300
2021
Q2 		$225K Sell
12,091
-12,728
-51% -$235K 0.09% 260
2021
Q1 		$444K Buy
24,819
+438
+2% +$7.42K 0.19% 165
2020
Q4 		$375K Sell
24,381
-1,292
-5% -$15.1K 0.16% 162
2020
Q3 		$284K Sell
25,673
-3,497
-12% -$41.1K 0.15% 236
2020
Q2 		$366K Buy
+29,170
New +$371K 0.17% 246

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Virtus ETF Advisers's XENE Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 1,802 shares — an estimated $70.6K sold.

Virtus ETF Advisers first reported a position in XENE in Q2 2020 and held it in 19 quarters. The position peaked at $444K in Q1 2021. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,802 Xenon Pharmaceuticals shares in Q1 2025, an estimated $70.6K.
  • Virtus ETF Advisers first reported a position in Xenon Pharmaceuticals in Q2 2020 and held it in 19 quarters.
  • Virtus ETF Advisers's Xenon Pharmaceuticals position peaked at $444K in Q1 2021.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.